Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis To Launch Bayer MS Therapy In 2009 To Build Market Presence

This article was originally published in The Pink Sheet Daily

Executive Summary

Deal with Bayer Schering aims to bolster Novartis’ presence ahead of a potential launch of FTY720, an oral multiple sclerosis treatment.

You may also be interested in...



New Brand, Same MS Drug: Novartis Launches Extavia In Europe

Novartis lays foundation for potential MS platform with European launch of its own branded version of Bayer-Schering’s Betaferon (interferon beta-1b).

New Brand, Same MS Drug: Novartis Launches Extavia In Europe

Novartis lays foundation for potential MS platform with European launch of its own branded version of Bayer-Schering’s Betaferon (interferon beta-1b).

Race To Develop Oral MS Therapy Heats Up As Novartis Releases Data Results

In Phase II studies, 77% of patients treated with Novartis' FTY720 remained relapse free after two years.

Topics

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel